Innate Pharma

Innate Pharma: Company Financial Information

 Company name  Innate Pharma SA    ISIN:  FR0010331421
 End of Fiscal Year:  31 December 2015    Founded Year:  2007

Innate Pharma

(at previous day's close)
Market Cap. 115.27 m
Shares In Issue 53.81 m
Prev. Close 2.14
PE Ratio -16.43  
Dividend Yield - %
EPS – basic -0.13 c
Dividend PS - c
Dividend Cover -
Cash Flow PS 3.86 c
Return On Equity (ROE) -9.14 %
Operating Margin - %
PEG Factor -  
EPS Growth Rate - %
Dividend PS Growth Rate - %
Net Debt -2.02 m
Gross Gearing 76.45 %
Quick Assets 245.86 m
Net Working Cap 245.79 m
Intangibles / Fixed Assets 0.26 %
Turnover PS 0.33 c
Pre-Tax Profit PS -0.00 c
Retained Profit PS - c
Cash PS 438.38 c
Net Cash PS 326.58 c
Net Tangible Asset Value PS* 70.23 c
Net Asset Value PS 568.54 c
Spread 0.01 (0.37%)

Innate Pharma Balance Sheet (31 Dec 2015)

IPH:liab eqIPH:assets

Innate Pharma Share Price

Sample Period  High Low
1 week 2.11 2.20
4 weeks 1.99 2.55
12 weeks 1.99 2.72
1 year 1.99 3.14

Innate Pharma (5 years)

Innate Pharma Historic Returns

Period *  Open Change % Open Avg. Avg. Daily Vol [m] Total Vol. [m] VWAP
1 week 2.14 0.00 0.09 2.14 69,427.00 2.15
4 weeks 2.02 0.12 6.04 2.12 173,941.00 2.19
12 weeks 2.69 -0.55 -20.37 2.21 140,240.00 2.21
26 weeks 2.92 -0.78 -26.64 2.50 146,325.00 2.51
1 year 4.30 -2.16 -50.19 2.94 205,742.00 3.20
3 years 5.78 -3.64 -62.94 4.00 387,754.00 4.44
5 years 5.11 -2.97 -58.08 4.79 328,688.00 4.99

Innate Pharma Key Management Ratio

Innate Pharma Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio 0.45  
PE Ratio -16.43  
Tobin's Q Ratio -  
Tobin's Q Ratio (excl. intangibles) -  
Dividend Yield - %
Market-to-Book Ratio 0.38  
Price-to-Pre-Tax Profit PS -171,410.61  
Price-to-Retained Profit PS -  
Price-to-Cash Flow PS 0.55  
Price-to-Sales PS 6.42  
Price-to-Net Tangible Asset Value PS 0.03  
Price-to-Cash PS 0.00  
Net Working Capital PS 4.57  
Price Pct to Working Capital PS 0.47 %
Earnings Yield - %
Average PE -  
Years in Average PE -  
PE to PE average - %

Innate Pharma Financial Ratios

(Leverage Ratios)
Debt Ratio -0.86 %
Debt-to-Equity Ratio -0.03  
Debt-to-Equity Ratio (excl. Intgbl) -0.03  
Debt-to-Equity Market Value -0.02  
Net Gearing -0.66 %
Net Gearing (excl. Intangibles) -0.68 %
Gross Gearing 76.45 %
Gross Gearing (excl. Intangibles) 78.96 %
Gearing Under 1 Year 19.66 %
Gearing Under 1 Year (excl. Intgbl) 20.31 %
Assets / Equity 4.25  
Cash / Equity 3.27  
(Liquidity Ratios)
Net Working Capital to Total Assets 80.34 %
Current Ratio 0.37  
Quick Ratio (Acid Test) 0.37  
Liquidity Ratio 3.92  
Cash & Equiv / Current Assets 1,047.56 %
(Solvency Ratios)
Enterprise Value 530.87 m
Sales 11.60  
CFO / Attributable Profit -  
CFO / Assets 0.00  
CFO / Debt 0.00  
Total Debt / Equity Market Value 2.03  
Total Debt / Sales 13.06  
Total Debt / Pre-Tax Profit -34,877,572.32  
Total Debt 233.89 m
Total Debt / Net Current Assets 0.95 %
(Dodds – Graham Ratios)
3 yr Compound Earnings Growth - %
5 yr Compound Earnings Growth - %
10 yr Compound Earnings Growth - %
Earn drops > 5% in 10yrs -  
Beta (60-Mnth) Beta (36-Mnth)
- -
Alpha (60-Mnth) Alpha (36-Mnth)
- -

Innate Pharma Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE) - %
Return On Assets (ROA) - %
Net Profit Margin - %
Assets Turnover -  
Return On Equity (ROE) -9.14 %
Return On Investment (ROI) - %
Dividend Payout Ratio - %
Plowback Ratio - %
Growth from Plowback Ratio - %
Net Income of Revenues - %
(Asset Utilisation Multiples)
Shareholders Equity Turnover -  
Fixed Assets Turnover -  
Current Assets Turnover -  
Net Working Capital Turnover -  
Inventory Turnover -  
(Other Operating Ratios)
Total Assets-to-Sales -  
Debtors-to-Sales - %
Debt Collection Period - Days

Innate Pharma Dividends

Type Curr. Dividend Amount Period Start Period End Total Dividend Amount
Final EUR - 31 Dec 2014 31 Dec 2015 -
Final EUR - 31 Dec 2013 31 Dec 2014 -
Final EUR - 31 Dec 2012 31 Dec 2013 -
Final EUR - 31 Dec 2011 31 Dec 2012 -
Final EUR - 31 Dec 2010 31 Dec 2011 -
Final EUR - 31 Dec 2009 31 Dec 2010 -
Final EUR - 31 Dec 2008 31 Dec 2009 -
Final EUR - 31 Dec 2007 31 Dec 2008 -

Innate Pharma Fundamentals

  31 Dec 2012 (EUR) 31 Dec 2013 (EUR) 31 Dec 2014 (EUR) 31 Dec 2015 (EUR)
Turnover 10.38 100.00% 12.47 100.00% 0.91 100.00% 17.91 100.00% m
Pre Tax Profit -2.83 -27.25% -2.47 -19.79% -25.99 -2,865.16% -6.71 -37.45% m
Attributable Profit - -% - -% - -% - -% m
Retained Profit - -% - -% - -% - -% m
Eps – Basic -0.08 -0.07 -0.39 -0.13
Eps – Diluted -0.08 -0.07 -0.39 -0.13
Dividends per Share - - - -

Innate Pharma Balance Sheet

  31 Dec 2012 (EUR) 31 Dec 2013 (EUR) 31 Dec 2014 (EUR) 31 Dec 2015 (EUR)
IPH:liab eqIPH:assets IPH:liab eqIPH:assets IPH:liab eqIPH:assets IPH:liab eqIPH:assets
  31 Dec 2012 (EUR) 31 Dec 2013 (EUR) 31 Dec 2014 (EUR) 31 Dec 2015 (EUR)
ASSETS
fixed assets  Fixed assets - -% - -% - -% - -% m
intangibles  Intangibles - -% - -% 5.36 5.91% 9.73 3.18% m
fixed investments  Fixed Investments 0.47 0.98% 0.27 0.49% - -% 37.79 12.35% m
current assets - other  Current Assets – Other 7.91 16.37% 7.02 12.56% 7.18 7.91% 12.29 4.02% m
stocks  Stocks 0.07 0.14% 0.18 0.32% 0.33 0.36% 0.28 0.09% m
debtors  Debtors 7.23 14.97% 7.06 12.64% 8.59 9.47% 9.95 3.25% m
cash & securities  Cash & securities 32.62 67.53% 41.35 73.99% 69.24 76.35% 235.91 77.11% m
Other assets - -% 0.00 0.00% 0.08 0.09% - -% m
TOTAL 48.30 100.00% 55.88 100.00% 90.69 100.00% 305.96 100.00% m
LIABILITIES
creditors - short  Creditors – Short 15.36 65.76% 9.28 23.03% 10.78 14.44% 60.16 83.48% m
creditors - long  Creditors – Long 9.57 40.95% 6.32 15.68% 5.29 7.09% 173.73 241.06% m
TOTAL 24.93 106.71% 15.60 38.71% 16.06 21.53% 233.89 324.54% m
EQUITY
Minority Interest -23.36 -100.00% -40.29 -100.00% -74.63 -100.00% -72.07 -100.00% m
Capital Reserves 23.36 100.00% 40.29 100.00% 74.63 100.00% 72.07 100.00% m
TOTAL 23.36 100.00% 40.29 100.00% 74.63 100.00% 72.07 100.00% m

Innate Pharma Cash Flow Statement

31 Dec 2012 (EUR) 31 Dec 2013 (EUR) 31 Dec 2014 (EUR) 31 Dec 2015 (EUR)
Operating CF -10.48 -11.11 -18.30 207.77
Investing CF -3.41 -0.96 -3.82 -122.30
Financial CF -2.15 19.82 48.12 3.17
Net change CF -16.03 7.75 25.99 88.65

Innate Pharma Employee Data

31 Dec 2012 (EUR) 31 Dec 2013 (EUR) 31 Dec 2014 (EUR) 31 Dec 2015 (EUR)
Number of employees 83.00 83.00 99.00 87.00
Sales per employee 0.13 0.15 0.01 0.21 m

Data supplied by
Your Recent History
EU
IPH
Innate Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221128 12:48:11